Manufacturer
PFIZER MANUFACTURING BELGIUM NV,
Contents
Hydrocortisone Na succinate
Indication
In situations requiring rapid & intense hormonal effect eg, acute adrenocortical insufficiency, bilateral adrenalectomy, severe shock, acute hypersensitivity reactions, overwhelming infections w/ severe toxicity, SLE in relapse, aspiration pneumonitis.
Instruction
This preparation may be administered by intravenous injection, by intravenous infusion, or by intramuscular injection, the preferred method for initial emergency use being intravenous injection. Following the initial emergency period, consideration should be given to employing a longer acting injectable preparation or an oral preparation.
Adult Initially 100-500 mg IV over 30 sec to 10 min. Dose may be repeated at 2-, 4- or 6-hr intervals.
Ped patient Initially 0.56-8 mg/kg daily in 3 or 4 divided doses (20-240 mg/m2 daily).
Drug interaction
Loss of corticosteroid-induced adrenal suppression w/ aminoglutethimide. Development of hypokalemia w/ K-depleting agents. Decreased clearance w/ macrolide antibiotics. Severe weakness in myasthenia gravis patient w/ anticholinesterases. Inhibition of response to warfarin. Increased blood glucose conc by antidiabetics. Decreased INH serum conc. Increased clearance by cholestyramine. Increased activity of both cyclosporine & corticosteroids. Increased risk of arrhythmias due to hypokalemia w/ digitalis glycosides. Decreased hepatic metabolism w/ estrogens eg, OCs. Enhanced metabolism by hepatic enzyme inducers eg, barbiturates, phenytoin, carbamazepine, rifampin. Increased plasma conc w/ hepatic enzyme inhibitors. Increased salicylate clearance.
Malaysia
